COLLEGE STATION, Texas, Nov. 3, 2025 -- Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a strategic partnership with Calidi Biotherapeutics, Inc. ("Calidi"), a clinical-stage immuno-oncology company developing next-generation oncolytic virus-based therapies. Under the agreement, Matica Bio will provide analytical development (AD), process development (PD), and GMP manufacturing to support the IND submission for CLD-401, the first lead from Calidi's RedTail platform a groundbreaking approach to genetic medicines. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic administration, replicate only in tumors cells, induce an immune priming event at the tumor site, and express high levels of IL-15 superagonist in the tumor microenvironment, a potent cytokine that induces NK and T-cell responses to the tumor.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
